Study of NMS-03305293 in Pts With Selected Advanced/Metastatic Solid Tumors
Status:
Recruiting
Trial end date:
2023-04-30
Target enrollment:
Participant gender:
Summary
Phase I, first-in-human, open-label, multicenter, dose-escalation study with the aim of
exploring safety, tolerability and preliminary antitumor activity of NMS-03305293 (a PARP
inhibitor) as single agent in adult patients with selected advanced/metastatic,
relapsed/refractory solid tumors who have exhausted standard treatment options or for whom
standard therapy is considered unsuitable.